Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
0.3059
USD
+5.77%
+3.59%
-1.00%
Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 10, 2022 at 04:03 pm EST
Daré Bioscience, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 7.02 million compared to USD 12.67 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.18 a year ago.
For the nine months, revenue was USD 10 million. Net loss was USD 15 million compared to USD 29.15 million a year ago. Basic loss per share from continuing operations was USD 0.18 compared to USD 0.45 a year ago.
Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Apr. 23
CI
Transcript : Daré Bioscience, Inc., 2023 Earnings Call, Mar 28, 2024
Mar. 28
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 28
CI
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Jan. 31
CI
Daré Bioscience, Inc. Announces Executive Changes
Jan. 26
CI
Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer
Jan. 26
CI
Dare Bioscience Says Chief Financial Officer Retiring, Chief Commercial Officer Has Resigned
Jan. 26
MT
Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study
Dec. 20
CI
Dare Bioscience Obtains FDA Clearance for Phase 2 Trial of Potential Dyspareunia Treatment
Dec. 07
MT
Dare Bioscience, Inc. Announces FDA Clearance of Investigational New Drug Application for DARE-VVA1
Dec. 07
CI
Dare Bioscience, Inc. Announces Commencement of Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Dec. 04
CI
Dare Bioscience Extends Agreement With Premier Research to Advance Reproductive Health Portfolio
Nov. 20
MT
Dar Bioscience, Inc. and Premier Research International LLC Extend Strategic Partnership to Accelerate the Clinical Development of Dar's Novel Women's Health Programs
Nov. 20
CI
HC Wainwright Trims Price Target on Dare Bioscience to $6 From $7, Keeps Buy Rating
Nov. 10
MT
Transcript : Daré Bioscience, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Nov. 09
Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023
Nov. 09
CI
Dare Bioscience Says Additional Data Show Sildenafil Cream Improving Sexual Disorder Symptoms
Nov. 01
MT
Sector Update: Health Care Stocks Rise Late Afternoon
23-10-16
MT
Sector Update: Health Care Stocks Gaining Monday Afternoon
23-10-16
MT
Dare Bioscience Triggers $1.8 Million Milestone Payment from Organon With Xaciato's First Shipment
23-10-16
MT
Dare Bioscience to Get $4.5 Million Grant Funding Installment for Development of Contraceptive Technology
23-09-21
MT
Dare Bioscience to Raise $7 Million in Registered Direct Offering of Shares, Warrants
23-08-30
MT
Transcript : Daré Bioscience, Inc., Q2 2023 Earnings Call, Aug 10, 2023
23-08-10
Daré Bioscience, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023
23-08-10
CI
Dare Bioscience Says Intravaginal Ring Showed Initial Efficacy in Treating Menopause Symptoms in Phase 1/2 Study
23-08-09
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
More about the company
Last Close Price
0.2892
USD
Average target price
4
USD
Spread / Average Target
+1,283.13%
Consensus
1st Jan change
Capi.
-1.00% 29.09M +1.51% 42.59B +8.57% 40.65B +49.22% 40.57B -12.36% 26.77B +8.92% 24.81B -25.13% 18.17B +29.17% 12.05B -3.12% 11.7B +6.35% 11.1B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1